Early treatment with Novartis' Mayzent stalls secondary progressive MS: study

21st April 2020 Uncategorised 0

Novartis is looking to grow its new multiple sclerosis drug Mayzent in a crowded field, and with Gilenya generics threatening, the newer MS medicine may need to carry even more weight. Tuesday, it racked up some new data that could help.

More: Early treatment with Novartis' Mayzent stalls secondary progressive MS: study
Source: fierce